Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Head and Neck Cancer
Interventions: Xevinapant, IMRT, Placebo; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more

Conditions: Influenza
Interventions: Peramivir, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 96
States / cities: Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more

Conditions: Asthma
Interventions: GSK5784283, Placebo, Standard of care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Contact Lenses, Extended-Wear
Interventions: Silicone Hydrogel Soft Contact Lenses; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 38 Years
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Allergic Rhinitis, Allergic Conjunctivitis
Interventions: Fluticasone Propionate Nasal Spray, Saline Nasal Spray; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Eosinophilic Asthma
Interventions: ICS-LABA, benralizumab, Placebo for Benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more

Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Interventions: Edwards PASCAL System, Abbott Mitraclip System; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more

Conditions: Overweight and Obesity, Type 2 Diabetes Mellitus
Interventions: Water, Glucose, Steviol Glycosides, Steviol Glycosides plus glucose, Rebaudioside A; Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 50 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Miami Gardens, Florida • Naples, Florida • Chicago, Illinois

Conditions: Allergic Conjunctivitis
Interventions: R89674 0.025% ophthalmic solution; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 10 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 6
States / cities: Louisville, Kentucky • North Andover, Massachusetts • Creve Coeur, Missouri + 3 more

Conditions: Anterior Cruciate Ligament Reconstruction
Interventions: Ropivacaine 0.5%, Percocet 7.5/325, Naprosyn 500 mg; Drug
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV-1-infection
Interventions: Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 51
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more

Conditions: Post Partum
Interventions: Plan B (Levonorgestrel); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 14 Years to 19 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gingivitis, Gingival Bleeding, Dental Plaque
Interventions: Device: Electric Flosser, Manual toothbrush; Device
Lead sponsor: Flaus, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Noblesville, Indiana

Conditions: Otitis Externa
Interventions: Ciprofloxacin/Dexamethasone, Ciprodex (R), Placebo; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 27
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 23 more

Conditions: Bleeding
Interventions: TachoSil®, Surgicel® Original; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more

Conditions: Breast Cancer
Interventions: Project SOAR Awakenings arm, Project SOAR comparison group; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Weight, Body Weight, Weight Bias, Weight Stigma, Physiological Stress, Biological Markers of Stress, Biological Markers of Inflammation, Eating Behaviors
Interventions: Behavioral Weight Management, Weight Bias Internalization; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 13 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Dysphonia
Interventions: Online Voice quality education module, Vocal hygiene module; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Petosemtamab, Investigator's Choice; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 59
States / cities: Mobile, Alabama • Prescott, Arizona • Scottsdale, Arizona + 51 more

Conditions: Metabolic Syndrome
Interventions: Dietary Intervention; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 21 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Mucosal Erosion, Gingival Recession
Interventions: Visual Analog scale (VAS) questionnaire, Vacuum-formed retainer (VFR) technique, 3-D printed acrylic resin stent (3DS) technique, Flowable resin composite stent (FRC) technique, Photographs of the patient's palate, Measuring graft dimensions, Chairside Polymer Stent; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Dental Plaque
Interventions: Protegera™ toothpaste (NaF), Crest™ Cavity Protection toothpaste (NaF); Drug
Lead sponsor: Protegera, Inc.; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Smoking Cessation
Interventions: placebo, varenicline; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Litchfield Park, Arizona • Los Angeles, California • Santa Ana, California + 9 more

Conditions: Essential Tremor of the Upper Limb
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more

Search by objective public record fields.

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)

A Comparison of 12 Month Daily Wear of Two Novel O2 Permeable Silicone Hydrogel CLs (HOP/SiH) and A Control, Standard O2 Lens

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release

Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

Anterior Cruciate Ligament Pain Study

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Advance Supply of Emergency Contraception Compared to Routine Postpartum Care in Teens

Clinical Assessment of the Safety and Efficacy of Flaus Electric Flosser on Plaque and Gingivitis Compared to a Manual Toothbrush

A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer

Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial

Assessing the Effects of Patient Self-Rating of Voice Quality on Voice Therapy Attendance and Outcomes

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

A Simple Dietary Message to Improve Dietary Quality for Metabolic Syndrome

Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques

Evaluation and Comparison of a Novel Dentrifice Formulation on Plaque Removal

Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm